These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33961299)

  • 21. Functional evaluation of CYP2C19 and CYP3A4 gene polymorphism on ibuprofen metabolism.
    Yuan LJ; Li XY; Ni JH; Wang J; Xu XY; Luo JC; Zhou Q; Hu GX; Cai JP; Qian JC
    Toxicol Appl Pharmacol; 2023 Sep; 475():116653. PubMed ID: 37574146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
    Wang A; Dorso C; Kopcho L; Locke G; Langish R; Harstad E; Shipkova P; Marcinkeviciene J; Hamann L; Kirby MS
    BMC Pharmacol; 2012 Apr; 12():2. PubMed ID: 22475049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.
    Xu RA; Wen J; Tang P; Wang C; Xie S; Zhang BW; Zhou Q; Cai JP; Hu GX
    Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):383-387. PubMed ID: 29117640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.
    Han M; Qian J; Ye Z; Xu R; Chen D; Xie S; Cai J; Hu G
    Chem Biol Interact; 2021 Aug; 345():109559. PubMed ID: 34153224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of recombinant CYP3A4 variants and interaction on imatinib metabolism in vitro.
    Chen J; Hu Y; Hu J; Ye Z; Lin Q; Cai JP; Hu GX; Xu RA
    Biomed Pharmacother; 2024 Nov; 180():117511. PubMed ID: 39366029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations.
    Xu XS; Demers R; Gu H; Christopher LJ; Su H; Cojocaru L; Boulton DW; Kirby M; Stouffer B; Humphreys WG; Arnold ME
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 889-890():77-86. PubMed ID: 22349123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of gene polymorphism on ticagrelor metabolism: an
    Hu X; Wang P; Zeng D; Hu GX
    PeerJ; 2024; 12():e18109. PubMed ID: 39346054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
    Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
    Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline.
    Hu X; Ni J; Gao N; Ye Z; Hu G; Cai J; Qian J
    Chem Biol Interact; 2022 Oct; 366():110123. PubMed ID: 36007633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influences of processed rhubarbs on the activities of four CYP isozymes and the metabolism of saxagliptin in rats based on probe cocktail and pharmacokinetics approaches.
    Gao J; Shi Z; Zhu S; Li GQ; Yan R; Yao M
    J Ethnopharmacol; 2013 Jan; 145(2):566-72. PubMed ID: 23207062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Saxagliptin overview: special focus on safety and adverse effects.
    Ali S; Fonseca V
    Expert Opin Drug Saf; 2013 Jan; 12(1):103-9. PubMed ID: 23137182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
    Golightly LK; Drayna CC; McDermott MT
    Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The variability in CYP3A4 activity determines the metabolic kinetic characteristics of ketamine.
    Li M; Li Q; Lin D; Zheng X; Jin L; Cai J; Hu G; Qian J
    Toxicology; 2023 Dec; 500():153682. PubMed ID: 38006927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and Functional Assessment of Eight
    Qi Y; Yang H; Wang S; Zou L; Zhao F; Zhang Q; Hong Y; Luo Q; Zhou Q; Geng P; Chen H; Ji F; Cai J; Dai D
    Drug Metab Dispos; 2024 Feb; 52(3):218-227. PubMed ID: 38195522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
    Yang LP
    Drugs; 2012 Jan; 72(2):229-48. PubMed ID: 22221000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional Analysis of Wild-Type and 27 CYP3A4 Variants on Dronedarone Metabolism
    Wang CC; Lan T
    Curr Drug Metab; 2022; 23(7):562-570. PubMed ID: 35702776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of flavonoids and CYP3A4 variants on midostaurin metabolism.
    Xu RA; Li QQ; Gao NY; Wang J; Li XY; Ye F; Ni JH; Hu GX; Qian JC
    Food Chem Toxicol; 2023 Apr; 174():113669. PubMed ID: 36805545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.